NCT05092373
- Conditions
- Adenocarcinoma, Adnexal Diseases, Advanced Breast Carcinoma, +110 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Stage IIIA2 Fallopian Tube Cancer AJCC V8
Explore clinical trials studying Stage IIIA2 Fallopian Tube Cancer AJCC V8. Study availability and eligibility vary by location and protocol.
5 public trials
2 recruiting studies
Stage IIIA2 Fallopian Tube Cancer AJCC V8 trial results
NCT05415709
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +47 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, Not Recruiting
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
NCT02650986
- Conditions
- Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +78 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
Active, Not Recruiting
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
NCT03943173
- Conditions
- Adnexal Diseases, BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, +45 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03907527
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +48 more
- Locations
-
- National Institutes of Health (NIH) Bethesda, Maryland, United States
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States